Skip to Main Content
LICENSES AND NOTICES

License for Use of "Physicians' Current Procedural Terminology", (CPT) Fourth Edition

End User/Point and Click Agreement: CPT codes, descriptions and other data only are copyright 2009 American Medical Association (AMA). All Rights Reserved (or such other date of publication of CPT). CPT is a trademark of the AMA.

You, your employees and agents are authorized to use CPT only as contained in the following authorized materials including but not limited to CGS fee schedules, general communications, Medicare Bulletin, and related materials internally within your organization within the United States for the sole use by yourself, employees, and agents. Use is limited to use in Medicare, Medicaid, or other programs administered by the Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to insure that your employees and agents abide by the terms of this agreement.

Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CPT for resale and/or license, transferring copies of CPT to any party not bound by this agreement, creating any modified or derivative work of CPT, or making any commercial use of CPT. License to use CPT for any use not authorized here in must be obtained through the AMA, CPT Intellectual Property Services, 515 N. State Street, Chicago, IL 60610. Applications are available at the AMA websiteExternal Website.

This product includes CPT which is commercial technical data and/or computer data bases and/or commercial computer software and/or commercial computer software documentation, as applicable which were developed exclusively at private expense by the American Medical Association, 515 North State Street, Chicago, Illinois, 60610. U.S. Government rights to use, modify, reproduce, release, perform, display, or disclose these technical data and/or computer data bases and/or computer software and/or computer software documentation are subject to the limited rights restrictions of DFARS 252.227-7015(b)(2)(June 1995) and/or subject to the restrictions of DFARS 227.7202-1(a)(June 1995) and DFARS 227.7202-3(a)June 1995), as applicable for U.S. Department of Defense procurements and the limited rights restrictions of FAR 52.227-14 (June 1987) and/or subject to the restricted rights provisions of FAR 52.227-14 (June 1987) and FAR 52.227-19 (June 1987), as applicable, and any applicable agency FAR Supplements, for non-Department Federal procurements.

AMA Disclaimer of Warranties and Liabilities.

CPT is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. AMA warrants that due to the nature of CPT, it does not manipulate or process dates, therefore there is no Year 2000 issue with CPT. AMA disclaims responsibility for any errors in CPT that may arise as a result of CPT being used in conjunction with any software and/or hardware system that is not Year 2000 compliant. No fee schedules, basic unit, relative values or related listings are included in CPT. The AMA does not directly or indirectly practice medicine or dispense medical services. The responsibility for the content of this file/product is with CGS or the CMS and no endorsement by the AMA is intended or implied. The AMA disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice if you violate its terms. The AMA is a third party beneficiary to this Agreement.

CMS Disclaimer

The scope of this license is determined by the AMA, the copyright holder. Any questions pertaining to the license or use of the CPT must be addressed to the AMA. End Users do not act for or on behalf of the CMS. CMS DISCLAIMS RESPONSIBILITY FOR ANY LIABILITY ATTRIBUTABLE TO END USER USE OF THE CPT. CMS WILL NOT BE LIABLE FOR ANY CLAIMS ATTRIBUTABLE TO ANY ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE INFORMATION OR MATERIAL CONTAINED ON THIS PAGE. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

This license will terminate upon notice to you if you violate the terms of this license. The AMA is a third party beneficiary to this license.

POINT AND CLICK LICENSE FOR USE OF "CURRENT DENTAL TERMINOLOGY", ("CDT")

End User License Agreement

These materials contain Current Dental Terminology, Fourth Edition (CDT), copyright © 2002, 2004 American Dental Association (ADA). All rights reserved. CDT is a trademark of the ADA.

THE LICENSE GRANTED HEREIN IS EXPRESSLY CONDITIONED UPON YOUR ACCEPTANCE OF ALL TERMS AND CONDITIONS CONTAINED IN THIS AGREEMENT. BY CLICKING BELOW ON THE BUTTON LABELED "I ACCEPT", YOU HEREBY ACKNOWLEDGE THAT YOU HAVE READ, UNDERSTOOD AND AGREED TO ALL TERMS AND CONDITIONS SET FORTH IN THIS AGREEMENT.

IF YOU DO NOT AGREE WITH ALL TERMS AND CONDITIONS SET FORTH HEREIN, CLICK BELOW ON THE BUTTON LABELED "I DO NOT ACCEPT" AND EXIT FROM THIS COMPUTER SCREEN.

IF YOU ARE ACTING ON BEHALF OF AN ORGANIZATION, YOU REPRESENT THAT YOU ARE AUTHORIZED TO ACT ON BEHALF OF SUCH ORGANIZATION AND THAT YOUR ACCEPTANCE OF THE TERMS OF THIS AGREEMENT CREATES A LEGALLY ENFORCEABLE OBLIGATION OF THE ORGANIZATION. AS USED HEREIN, "YOU" AND "YOUR" REFER TO YOU AND ANY ORGANIZATION ON BEHALF OF WHICH YOU ARE ACTING.

  1. Subject to the terms and conditions contained in this Agreement, you, your employees, and agents are authorized to use CDT-4 only as contained in the following authorized materials and solely for internal use by yourself, employees and agents within your organization within the United States and its territories. Use of CDT-4 is limited to use in programs administered by Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to ensure that your employees and agents abide by the terms of this agreement. You acknowledge that the ADA holds all copyright, trademark and other rights in CDT-4. You shall not remove, alter, or obscure any ADA copyright notices or other proprietary rights notices included in the materials.
  2. Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CDT-4 for resale and/or license, transferring copies of CDT-4 to any party not bound by this agreement, creating any modified or derivative work of CDT-4, or making any commercial use of CDT-4. License to use CDT-4 for any use not authorized herein must be obtained through the American Dental Association, 211 East Chicago Avenue, Chicago, IL 60611. Applications are available at the American Dental Association websiteExternal Website.
  3. Applicable Federal Acquisition Regulation Clauses (FARS)\Department of Defense Federal Acquisition Regulation Supplement (DFARS) Restrictions Apply to Government use. Please click here to see all U.S. Government Rights Provisions.
  4. ADA DISCLAIMER OF WARRANTIES AND LIABILITIES. CDT-4 is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. No fee schedules, basic unit, relative values or related listings are included in CDT-4. The ADA does not directly or indirectly practice medicine or dispense dental services. The sole responsibility for the software, including any CDT-4 and other content contained therein, is with (insert name of applicable entity) or the CMS; and no endorsement by the ADA is intended or implied. The ADA expressly disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice to you if you violate the terms of this Agreement. The ADA is a third-party beneficiary to this Agreement.
  5. CMS DISCLAIMER. The scope of this license is determined by the ADA, the copyright holder. Any questions pertaining to the license or use of the CDT-4 should be addressed to the ADA. End users do not act for or on behalf of the CMS. CMS DISCLAIMS RESPONSIBILITY FOR ANY LIABILITY ATTRIBUTABLE TO END USER USE OF THE CDT-4. CMS WILL NOT BE LIABLE FOR ANY CLAIMS ATTRIBUTABLE TO ANY ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE INFORMATION OR MATERIAL COVERED BY THIS LICENSE. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

The license granted herein is expressly conditioned upon your acceptance of all terms and conditions contained in this agreement. If the foregoing terms and conditions are acceptable to you, please indicate your agreement by clicking below on the button labeled "I ACCEPT". If you do not agree to the terms and conditions, you may not access or use the software. Instead, you must click below on the button labeled "I DO NOT ACCEPT" and exit from this computer screen.


Impact

Print | Bookmark | Email | Font Size: + |

May 23, 2024

July 2024 HCPCS Updates – New, Revised, and Discontinued HCPCS Codes and Modifiers – Revised

The following information is based on the July 2024 Healthcare Common Procedure Coding System (HCPCS) file. There are several updates that will be effective July 1, 2024. Please keep in mind that the appearance of a HCPCS code is not an indication of coverage by the DME MAC.

This following list contains added HCPCS codes that will be effective July 1, 2024.

HCPCS DESCRIPTION
J0211 Injection, sodium nitrite 3 mg and sodium thiosulfate 125 mg (nithiodote)
J0687 Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg
J0872 Injection, daptomycin (xellia), unrefrigerated, not therapeutically equivalent to j0878 or j0873, 1 mg
J1597 Injection, glycopyrrolate (glyrx-pf), 0.1 mg
J1598 Injection, glycopyrrolate (fresenius kabi), not therapeutically equivalent to j1596, 0.1 mg
J1748 Injection, infliximab-dyyb (zymfentra), 10 mg
J2183 Injection, meropenem (wg critical care), not therapeutically equivalent to j2185, 100 mg
J2246 Injection, micafungin in sodium (baxter), not therapeutically equivalent to j2248, 1 mg
J2267 Injection, mirikizumab-mrkz, 1 mg
J2373 Injection, phenylephrine hydrochloride (immphentiv), 20 micrograms
J2468 Injection, palonosetron hydrochloride (avyxa), not therapeutically equivalent to j2469, 25 micrograms
J2470 Injection, pantoprazole sodium, 40 mg
J2471 Injection, pantoprazole (hikma), not therapeutically equivalent to j2470, 40 mg
J3247 Injection, secukinumab, intravenous, 1 mg
J3263 Injection, toripalimab-tpzi, 1 mg
J3393 Injection, betibeglogene autotemcel, per treatment
J3394 Injection, lovotibeglogene autotemcel, per treatment
J7171 Injection, adamts13, recombinant-krhn, 10 iu
J8611 Methotrexate (jylamvo), oral, 2.5 mg
J8612 Methotrexate (xatmep), oral, 2.5 mg
J9361 Injection, efbemalenograstim alfa-vuxw, 0.5 mg
Q5137 Injection, ustekinumab-auub (wezlana), biosimilar, subcutaneous, 1 mg
Q5138 Injection, ustekinumab-auub (wezlana), biosimilar, intravenous, 1 mg

The following HCPCS codes have description/verbiage changes that will be effective July 1, 2024.

HCPCS DESCRIPTION
J0134 Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg
J0136 Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg
J0137 Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg
J0173 Injection, epinephrine (belcher), not therapeutically equivalent to j0171, 0.1 mg
J0401 Injection, aripiprazole (abilify maintena), 1 mg
J0651 Injection, levothyroxine sodium (fresenius kabi), not therapeutically equivalent to j0650, 10 mcg
J0652 Injection, levothyroxine sodium (hikma), not therapeutically equivalent to j0650, 10 mcg
J0873 Injection, daptomycin (xellia), not therapeutically equivalent to j0878 or j0872, 1 mg
J0893 Injection, decitabine (sun pharma), not therapeutically equivalent to j0894, 1 mg
J1574 Injection, ganciclovir sodium (exela), not therapeutically equivalent to j1570, 500 mg
J1806 Injection, esmolol hydrochloride (wg critical care), not therapeutically equivalent to j1805, 10 mg
J1921 Injection, labetalol hydrochloride (hikma), not therapeutically equivalent to j1920, 5 mg
J2021 Injection, linezolid (hospira), not therapeutically equivalent to j2020, 200 mg
J2184 Injection, meropenem (b. braun), not therapeutically equivalent to j2185, 100 mg
J2251 Injection, midazolam hydrochloride (wg critical care), not therapeutically equivalent to j2250, per 1 mg
J2272 Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg
J2281 Injection, moxifloxacin (fresenius kabi), not therapeutically equivalent to j2280, 100 mg
J2599 Injection, vasopressin (american regent), not therapeutically equivalent to j2598, 1 unit
J2806 Injection, sincalide (maia), not therapeutically equivalent to j2805, 5 micrograms
J3244 Injection, tigecycline (accord), not therapeutically equivalent to j3243, 1 mg
J3371 Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg
J3372 Injection, vancomycin hcl (xellia), not therapeutically equivalent to j3370, 500 mg
J9046 Injection, bortezomib (dr. reddy's), not therapeutically equivalent to j9041, 0.1 mg
J9172 Injection, docetaxel (ingenus), not therapeutically equivalent to j9171, 1 mg
J9258 Injection, paclitaxel protein-bound particles (teva), not therapeutically equivalent to j9264, 1 mg
J9259 Injection, paclitaxel protein-bound particles (american regent), not therapeutically equivalent to j9264, 1 mg
J9294 Injection, pemetrexed (hospira), not therapeutically equivalent to j9305, 10 mg
J9296 Injection, pemetrexed (accord), not therapeutically equivalent to j9305, 10 mg
J9314 Injection, pemetrexed (teva), not therapeutically equivalent to j9305, 10 mg
J9322 Injection, pemetrexed (blue point), not therapeutically equivalent to j9305, 10 mg
J9393 Injection, fulvestrant (teva), not therapeutically equivalent to j9395, 25 mg
Q2055 Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

The following listing contains discontinued HCPCS codes, along with the cross-walked HCPCS codes (if applicable). Please note, not all discontinued HCPCS codes will have a cross-walked HCPCS code.

HCPCS DISCONTINUE DATE CROSSWALK HCPCS CODE
J2780 06/30/2024  
J9371 06/30/2024  

Publication History:

May 23, 2024 Originally published
June 27, 2024 Added J7171 - Injection, adamts13, recombinant-krhn, 10 iu

spacer

26 Century Blvd Ste ST610, Nashville, TN 37214-3685 © 2025 CGS Administrators, LLC. All Rights Reserved